Engaging European society at the forefront of cancer research and care

Baumann, Michaël; Celis, Julio E.; Ringborg, Ulrik; Heitor, M. V.; Berns, Anton; Albreht, Tit; Arabadjiev, Jeliazko; Boutros, Michael; Brandenburg, Mario; Canhão, Helena; Carneiro, Fátima; Chomienne, Christine; Lorenzo, Francesco De; Eggermont, Alexander M.M.; Font, Angel; Garralda, Elena; Goulart, Margarida; Henrique, Rui; Lawler, Mark; Maier-Hein, Lena; Meunier, Françoise; Oberst, Simon; Oliveira, Pedro; Papatriantafyllou, Maria; Schüz, Joachim; Solary, Éric; Valencia, Alfonso; Vargas, Rosalia; Weiderpass, Elisabete; Wilking, Nils

doi:10.1002/1878-0261.13423

Cited by 5 publications

(3 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…By unifying the cancer community together with main cancer organizations, the EACS has spoken with a single voice in advising the EC about (a) present unmet needs in prevention and therapeutics/care, (b) the role of translational cancer research in meeting the requirements, (c) the role of CCCs and advanced infrastructures, (d) structuring collaboration for the development of personalized/precision cancer medicine and (e) developing science policy and strategies to decrease inequalities [13][14][15][16][17].…”

Section: Achievements and Lessons Learnedmentioning

confidence: 99%

From the creation of the European research area in 2000 to a Mission on cancer in Europe in 2021‐lessons learned and implications

Celis,

Ringborg

2024

Molecular Oncology

Self Cite

View full text Add to dashboard Cite

In the year 2000, cancer research in Europe had the potential to make a difference as it had several unique strengths, such as a strong foundation in biomedical science, good patient registries, infrastructures that spanned from biological repositories to bioinformatic hubs as well as thriving Comprehensive Cancer Centers (CCCs) and basic/preclinical cancer research institutions of high international standing. Research, however, was fragmented and lacked coordination. As a result, Europe could not harness its potential for translating basic research discoveries into a clinical setting for the patients' benefit. What was needed was a paradigm shift in cancer research that addressed the translational research continuum. Along these lines, in 2000, European Union (EU) Commissioner Philippe Busquin established the European Research Area (ERA) and in 2002 the European Cancer Research Area (ECRA), and their political approval was a powerful catalyst for the increased involvement of scientists in science policy in the EU. In this report, we briefly describe the actions embraced by the cancer community and cancer organizations in response to Busquin's proposals that led to the creation of the EU Mission on Cancer (MoC) in Horizon 2020 in 2021.

show abstract

Section: Achievements and Lessons Learnedmentioning

confidence: 99%

From the creation of the European research area in 2000 to a Mission on cancer in Europe in 2021‐lessons learned and implications

Celis,

Ringborg

2024

Molecular Oncology

Self Cite

View full text Add to dashboard Cite

show abstract

“…"UNCAN.eu" refers to a collective European effort that seeks to enable a step forward in our understanding of cancer. A key goal of UNCAN.eu is to identify cancer research priorities and expectations from patients and the general public and, ultimately, to consider them in the definition of the portfolio of near-future research and innovation actions [21,22]. A survey was conducted by the ECPC and the CCI-E to take account of patients' and citizens' perspectives.…”

Section: A Survey Of Patientsmentioning

confidence: 99%

Mobilising Collaboration among Stakeholders to Optimise the Growing Potential of Data for Tackling Cancer

Horgan,

Van den Bulcke,

Malapelle

et al. 2023

JMP

Self Cite

View full text Add to dashboard Cite

Effective cancer diagnosis, treatment and control depend on interactions among numerous distinct factors, from technology to data to skills to sociology. But a crucial influence is the extent to which the health system takes account of the distinct perspectives of the many different groups of interdependent stakeholders concerned with cancer, including patients, practitioners and planners. This paper provides some elucidation as to how far and how efficiently these interactions currently take place in Europe. It also makes some tentative suggestions as to how conscious systematic interventions could improve cancer outcomes. It is based on a series of expert panels and surveys conducted by the European Alliance for Personalised Medicine (EAPM) that provided information at the national level on three selected parameters: implementation of next-generation sequencing (NGS) and liquid biopsy (LB), attitudes of patients to prevention and practices of sharing genomic data among healthcare professionals (HCPs). The varying data infrastructure highlights the urgent need for substantial improvements to accommodate the increasing importance of genomics data in cancer diagnosis and care. Additionally, we identify disparities in age-specific approaches to cancer prevention, emphasising the necessity for tailored strategies to address unique age group perspectives. Moreover, distinct regional prioritizations in cancer treatment underscore the importance of considering regional variations when shaping future cancer care strategies. This study advocates for collaborative data sharing supported by technological innovation to overcome these challenges, ultimately fostering a holistic and equitable provision of cancer care in Europe.

show abstract

“…The EORTC-ESTRO Radiation Infrastructure for Europe (E2RADIatE) is highlighted as a valuable tool for prospective clinical trials. The sustainability of such platforms is a major concern, calling for support from governments and funding agencies to benefit patients and society by advancing therapeutic strategies that truly make a difference [37][38][39][40].…”

mentioning

confidence: 99%

Demographic Analysis of Cancer Research Priorities and Treatment Correlations

Horgan,

Van den Bulcke,

Malapelle

et al. 2024

Current Oncology

Self Cite

View full text Add to dashboard Cite

Understanding the diversity in cancer research priorities and the correlations among different treatment modalities is essential to address the evolving landscape of oncology. This study, conducted in collaboration with the European Cancer Patient Coalition (ECPC) and Childhood Cancer International-Europe (CCI-E) as part of the “UNCAN.eu” initiative, analyzed data from a comprehensive survey to explore the complex interplay of demographics, time since cancer diagnosis, and types of treatments received. Demographic analysis revealed intriguing trends, highlighting the importance of tailoring cancer research efforts to specific age groups and genders. Individuals aged 45–69 exhibited highly aligned research priorities, emphasizing the need to address the unique concerns of middle-aged and older populations. In contrast, patients over 70 years demonstrated a divergence in research priorities, underscoring the importance of recognising the distinct needs of older individuals in cancer research. The analysis of correlations among different types of cancer treatments underscored the multidisciplinary approach to cancer care, with surgery, radiotherapy, chemotherapy, precision therapy, and biological therapies playing integral roles. These findings support the need for personalized and combined treatment strategies to achieve optimal outcomes. In conclusion, this study provides valuable insights into the complexity of cancer research priorities and treatment correlations in a European context. It emphasizes the importance of a multifaceted, patient-centred approach to cancer research and treatment, highlighting the need for ongoing support, adaptation, and collaboration to address the ever-changing landscape of oncology.

show abstract

Engaging European society at the forefront of cancer research and care

Cited by 5 publications

References 38 publications

From the creation of the European research area in 2000 to a Mission on cancer in Europe in 2021‐lessons learned and implications

From the creation of the European research area in 2000 to a Mission on cancer in Europe in 2021‐lessons learned and implications

Mobilising Collaboration among Stakeholders to Optimise the Growing Potential of Data for Tackling Cancer

Demographic Analysis of Cancer Research Priorities and Treatment Correlations

Contact Info

Product

Resources

About